Three-Dimensional H-Scan Ultrasound Imaging of Early Breast Cancer Response to Neoadjuvant Therapy in a Murine Model.

Autor:	Tai H; From the Departments of Electrical and Computer Engineering., Song J; Bioengineering, University of Texas at Dallas, Richardson, TX., Li J; Bioengineering, University of Texas at Dallas, Richardson, TX., Reddy S; Bioengineering, University of Texas at Dallas, Richardson, TX., Khairalseed M; Bioengineering, University of Texas at Dallas, Richardson, TX., Hoyt K; Bioengineering, University of Texas at Dallas, Richardson, TX.
Jazyk:	angličtina
Zdroj:	Investigative radiology [Invest Radiol] 2022 Apr 01; Vol. 57 (4), pp. 222-232.
DOI:	10.1097/RLI.0000000000000831
Abstrakt:	Objectives: Three-dimensional (3D) H-scan is a new ultrasound (US) technique that images the relative size of acoustic scatterers. The goal of this research was to evaluate use of 3D H-scan US imaging for monitoring early breast cancer response to neoadjuvant therapy using a preclinical murine model of breast cancer. Materials and Methods: Preclinical studies were conducted using luciferase-positive breast cancer-bearing mice (n = 40). Anesthetized animals underwent US imaging at baseline before administration with an apoptosis-inducing drug or a saline control. Image data were acquired using a US scanner equipped with a volumetric transducer following either a shorter- or longer-term protocol. The later included bioluminescent imaging to quantify tumor cell viability. At termination, tumors were excised for ex vivo analysis. Results: In vivo results showed that 3D H-scan US imaging is considerably more sensitive to tumor changes after apoptosis-inducing drug therapy as compared with traditional B-scan US. Although there was no difference at baseline (P > 0.99), H-scan US results from treated tumors exhibited progressive decreases in image intensity (up to 62.2% by day 3) that had a significant linear correlation with cancer cell nuclear size (R2 > 0.51, P < 0.001). Results were validated by histological data and a secondary longitudinal study with survival as the primary end point. Discussion: Experimental results demonstrate that noninvasive 3D H-scan US imaging can detect an early breast tumor response to apoptosis-inducing drug therapy. Local in vivo H-scan US image intensity correlated with cancer cell nuclear size, which is one of the first observable changes of a cancer cell undergoing apoptosis and confirmed using histological techniques. Early imaging results seem to provide prognostic insight on longer-term tumor response. Overall, 3D H-scan US imaging is a promising technique that visualizes the entire tumor and detects breast cancer response at an early stage of therapy. Competing Interests: Conflicts of interest and sources of funding: The authors declare no conflicts of interest. This research was supported in part by National Institutes of Health grants R01DK126833 and R01EB025841 and award RP180670 from the Cancer Prevention and Research Institute of Texas to establish the Small Animal Imaging Facility at the University of Texas at Dallas. (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu